Literature DB >> 20540691

Systematic evaluation of dose proportionality studies in clinical pharmacokinetics.

Yucheng Sheng1, Yingchun He, Xiaohui Huang, Juan Yang, Kun Wang, Qingshan Zheng.   

Abstract

An understanding of dose proportionality is essential in drug development, and the results are of great clinical importance for predicting the effects of dose adjustments. However, little consensus exists with regard to study design and analysis. The aim of this paper was to produce a detailed profile of the information on dose proportionality studies in the last 10 years and to provide a foundation for reflection and debate on future priorities. A total of 147 publications comprising 156 studies were analyzed. The typical dose proportionality study enrolled 20 to 30 subjects and randomly allocated them into 3 to 4 dose levels to investigate pharmacokinetic behaviors within a dose ratio range of 2-6. The most common design was the crossover experiment (52.6%), and evaluating dose-adjusted pharmacokinetic parameters followed by hypothesis testing (43%) was the most frequent statistical approach. However, the alternative crossover design and equivalence criterion based on the power model represented only 4% and 8% of studies, respectively. The power model as a recommendable empirical relationship to assess dose proportionality was applied in 25 (16%) studies. This research suggests that the alternative crossover design and power model statistical method should be attracting more attention in order to obtain more information in studies with limited subjects.

Mesh:

Substances:

Year:  2010        PMID: 20540691     DOI: 10.2174/138920010791636185

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  7 in total

1.  A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers.

Authors:  Nan Zhao; Bo Jia; Hong Zhao; Junyu Xu; Xiaoyan Sheng; Lin Luo; Zhangma Huang; Xingan Wang; Qingyun Ren; Yingjun Zhang; Xia Zhao; Yimin Cui
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.

Authors:  Nan Zhao; Ran Xie; Xia Zhao; Hong Zhao; Bo Jia; Yingjun Zhang; Lin Luo; Zhangma Huang; Jing Li; Xingan Wang; Huan Yan; Bixia He; Hongming Xie; Qingyun Ren; Yimin Cui
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

3.  Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.

Authors:  Yo Han Kim; Hee Youn Choi; Yook-Hwan Noh; Shi Hyang Lee; Hyeong-Seok Lim; Chin Kim; Kyun-Seop Bae
Journal:  Drug Des Devel Ther       Date:  2015-06-08       Impact factor: 4.162

Review 4.  Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.

Authors:  Grace Chen; Astrid-Maria Højer; Johan Areberg; George Nomikos
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

5.  Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.

Authors:  Cuiyun Li; Min Wu; Hong Zhang; Jiajia Mai; Lizhi Yang; Yanhua Ding; Junqi Niu; John Mao; Wenqiang Wu; Dong Zhang; Yanan Tang; Wenhao Yan
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

6.  Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study.

Authors:  Kwang-Hee Shin; Ji-Young Jeon; Kyungho Jang; Tae-Eun Kim; Min-Gul Kim
Journal:  Drug Des Devel Ther       Date:  2018-10-11       Impact factor: 4.162

7.  Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.

Authors:  Himanshu Naik; Deb J Steiner; Mark Versavel; Joanne Palmer; Regan Fong
Journal:  Clin Transl Sci       Date:  2020-12-13       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.